FDA's Yearly Germ Testing Guidelines Get Refreshed
Published Date: 5/12/2026
Notice
Summary
The FDA just dropped its yearly update on how it tests germs to see which medicines work best. This affects doctors, labs, and drug makers who rely on these test rules to fight infections smarter and faster. The updates keep everyone on the same page and help save time and money by improving treatment choices—comments on these changes are open now!
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16728, Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer
The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Cystoscopic system intended as an aid for detection of bladder cancer," along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16727, Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), all postamendments class III (premarket approval) devices, into class II (special controls), subject to premarket notification. FDA is also establishing a new device classification regulation, along with the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of this device type.
Previous / Next Documents
Previous: 2026-09437, Agency Information Collection Activities; Submission for OMB Review; Comment Request; Opportunity Zones Nomination Tool
The Treasury Department is updating its Opportunity Zones Nomination Tool, which helps states pick low-income areas for special tax breaks to encourage investment and job growth. They’re asking the public to comment by June 11, 2026, before sending the updated form for approval. This change keeps the program alive and kicking, making it easier for investors to support communities that need it most.
Next: 2026-09439, Certain Ink Cartridges and Components Thereof II; Notice of a Commission Determination To Review in Part an Initial Determination Granting Complainants' Motion for Summary Determination of Violation; Request for Written Submissions on the Issues Under Review and on Remedy, the Public Interest, and Bonding
The U.S. International Trade Commission is taking a second look at a decision that found certain ink cartridges and parts violated Epson’s patents. They’re asking for written opinions on what should happen next, including possible fixes, public impact, and money matters. This affects companies importing or selling these ink cartridges and could lead to changes in what’s allowed or blocked soon.